The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sravani Reddy Gantla
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts less than Nifty Microcap 250 and 2.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sravani Reddy Gantla, a non-promoter shareholder of Oxygenta Pharmaceutical Ltd, has disclosed the sale of 19,79,340 equity shares (5.35% of total share capital) on April 16, 2025. Before the sale, she held 44,87,000 shares (12.13%), and after the sale her holding stands at approximately 25,07,660 shares (around 6.78% of capital). The transfer was executed off-market via a Memorandum of Understanding dated September 30, 2024, suggesting a pre-arranged deal rather than an open-market transaction. The company's total equity capital remains 3,69,83,500 shares of Rs. 10 each (Rs. 36.98 crore). The filing was submitted to BSE on April 19, 2025, in compliance with SEBI takeover regulations.
Since the seller is not a promoter, this is not a promoter exit event and likely reflects a pre-negotiated private transfer. Shareholders should monitor whether the buyer of these shares is a known entity, as a 5.35% off-market block deal could signal a change in the shareholder base or potential future strategic involvement.